Literature DB >> 1676752

Regulatory T cell activity specific to human type II and III collagens in rheumatoid arthritis.

O Elkayam1, H Zinger, E Zisman, R Segal, M Yaron, C Brautbar, E Mozes.   

Abstract

Fifty-one patients with rheumatoid arthritis (RA) were examined for their immune response potential to human collagen type II and III. It was found that T cells of 57% of patients with RA proliferated to collagen type III whereas only 27% of T cells of patients with osteoarthritis (OA) and healthy controls responded to this antigen by proliferation (p less than 0.04). A lower percentage (38%) of patients with RA had proliferative responses to collagen type II in comparison to 17% of responders in healthy controls. The capability to produce T cell helper factors specific to collagen type III was found to be significantly higher in patients treated with nonsteroidal antiinflammatory drugs (NSAID) (60%) in comparison to patients with OA (16%) and healthy controls (13%). Immunoregulatory drugs affected the specific T helper function in response to collagen type III but did not change the proliferative responses to collagen type II and III in patients with RA. HLA analyses revealed a significant difference in the frequency of HLA-DRw10 between our sample of patients with RA and healthy controls.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1676752

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  3 in total

Review 1.  A reappraisal of the evidence that rheumatoid arthritis and several other idiopathic diseases are slow bacterial infections.

Authors:  G A Rook; P M Lydyard; J L Stanford
Journal:  Ann Rheum Dis       Date:  1993-03       Impact factor: 19.103

Review 2.  Rheumatoid arthritis: how well do the theories fit the evidence?

Authors:  J McCulloch; P M Lydyard; G A Rook
Journal:  Clin Exp Immunol       Date:  1993-04       Impact factor: 4.330

Review 3.  Can we induce tolerance in rheumatoid arthritis?

Authors:  A E Postlethwaite
Journal:  Curr Rheumatol Rep       Date:  2001-02       Impact factor: 4.686

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.